NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
55513-0004-04 | 55513-0004 | Darbepoetin alfa | Aranesp | 60.0 ug/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Sep 11, 2006 | In Use | ||
00093-7290-56 | 00093-7290 | Raloxifene Hydrochloride | Raloxifene Hydrochloride | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Mar 28, 2014 | In Use | ||
55513-0005-01 | 55513-0005 | Darbepoetin alfa | Aranesp | 100.0 ug/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Sep 11, 2006 | In Use | ||
68083-0279-01 | 68083-0279 | Levoleucovorin | levoleucovorin | 10.0 mg/mL | Ancillary Therapy | Chemoprotective | Antidote | Intravenous | Sep 20, 2018 | In Use | |
00002-5340-60 | 00002-5340 | Selpercatinib | RETEVMO | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, RET | Oral | Apr 10, 2024 | In Use | |
00555-0899-02 | 00555-0899 | Estradiol | Estradiol | 0.5 mg/1 | Hormonal Therapy | Estrogen | Oral | Oct 28, 1997 | In Use | ||
67877-0184-02 | 67877-0184 | Granisetron Hydrochloride | Granisetron Hydrochloride | 1.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jan 1, 2010 | In Use | |
42254-0097-10 | 42254-0097 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Aug 2, 2007 | In Use | |
58468-0357-01 | 58468-0357 | Alemtuzumab | Campath | 30.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD52 | Intravenous | Nov 30, 2009 | In Use | |
49315-0009-07 | 49315-0009 | Doxorubicin hydrochloride | DOXORUBICIN HYDROCHLORIDE | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Sep 14, 2020 | In Use | |
00093-7473-06 | 00093-7473 | Capecitabine | Capecitabine | 150.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Mar 7, 2014 | In Use | |
64205-0488-30 | 64205-0488 | Estradiol | Estradiol | 2.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Mar 14, 1996 | In Use | ||
59651-0487-78 | 59651-0487 | PREDNISONE | PREDNISONE | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Mar 28, 2022 | In Use | |
68382-0775-01 | 68382-0775 | Methotrexate | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Feb 9, 2017 | In Use | |
00006-3026-02 | 00006-3026 | Pembrolizumab | Keytruda | 25.0 mg/mL | Immunotherapy | Checkpoint Inhibitor | PD-1 | Intravenous | Jan 15, 2015 | In Use | |
68001-0557-00 | 68001-0557 | Methylprednisolone | Methylprednisolone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jan 31, 2023 | In Use | |
00781-2323-68 | 00781-2323 | Aprepitant | Aprepitant | 125.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | Dec 27, 2016 | In Use | |
70934-0605-30 | 70934-0605 | Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 10.0 mg/1 | Hormonal Therapy | Progestin | Oral | Mar 12, 2020 | In Use | ||
00093-7474-89 | 00093-7474 | Capecitabine | Capecitabine | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Mar 7, 2014 | In Use | |
71335-1516-02 | 71335-1516 | Prednisone | Prednisone | 50.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Feb 20, 2020 | In Use | |
72189-0183-60 | 72189-0183 | Estradiol | Estradiol | 1.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Feb 24, 2021 | In Use | ||
62175-0242-24 | 62175-0242 | Temozolomide | Temozolomide | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Feb 10, 2016 | In Use | |
68151-1668-08 | 68151-1668 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/5mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Dec 26, 2006 | In Use | |
55154-3680-00 | 55154-3680 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jun 27, 2007 | In Use | |
55513-0126-01 | 55513-0126 | Epoetin alfa | Epogen | 2000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Jun 30, 1989 | In Use |
Found 11120 results — Export these results